PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26758248-2 2016 In our study, allogeneic polyclonal CD4 (+) CD25 (+) Tregs and CD4 (+) CD25 (+) CD127(lo)Tregs expanded in vitro in the presence of rapamycin and low dose IL-2 suppressed proliferation of 11 out of 12 established lymphoma B-cell lines. Sirolimus 132-141 CD4 molecule Homo sapiens 63-66 29551338-19 2018 Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. Sirolimus 0-9 CD4 molecule Homo sapiens 19-22 29551338-19 2018 Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. Sirolimus 0-9 CD4 molecule Homo sapiens 150-153 29551338-19 2018 Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. Sirolimus 0-9 CD4 molecule Homo sapiens 150-153 27400793-6 2016 Our results demonstrated that rapamycin strengthened the capacity of MSCs to inhibit CD4+ T-cell proliferation, whereas 3-MA weakened the inhibitory ability of MSCs. Sirolimus 30-39 CD4 molecule Homo sapiens 85-88 30061014-9 2018 Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV. Sirolimus 34-43 CD4 molecule Homo sapiens 82-85 30061014-9 2018 Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV. Sirolimus 34-43 CD4 molecule Homo sapiens 97-100 30061014-9 2018 Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV. Sirolimus 34-43 CD4 molecule Homo sapiens 97-100 27974559-12 2017 Here we found that rapamycin treatment predominantly inhibited GC B cell responses during viral infection and that this led to biased helper CD4 T cell differentiation as well as impaired antibody responses. Sirolimus 19-28 CD4 molecule Homo sapiens 141-144 26758248-6 2016 CD4 (+) CD25 (+) Tregs or CD4 (+) CD25 (+) CD127(lo)Tregs expanded ex vivo with rapamycin could be used to suppress regrowth of residual lymphoma after autologous hematopoietic cell transplantation (HCT), and to counteract both graft-versus-host disease and lymphoma re-growth after allogeneic HCT in select patients with lymphoma susceptible to the regulation by Tregs. Sirolimus 80-89 CD4 molecule Homo sapiens 26-29 25354238-6 2015 Sirolimus conversion led to an increase in CD4(+)25(+++)Foxp3(+) regulatory T cells. Sirolimus 0-9 CD4 molecule Homo sapiens 43-46 26037126-7 2015 Treatment with rapamycin increased survival, blocked breakdown of the blood-brain barrier and brain hemorrhaging, decreased the influx of both CD4(+) and CD8(+) T cells into the brain and the accumulation of parasitized red blood cells in the brain. Sirolimus 15-24 CD4 molecule Homo sapiens 143-146 27569951-5 2016 CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups. Sirolimus 165-174 CD4 molecule Homo sapiens 0-3 27569951-5 2016 CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups. Sirolimus 176-180 CD4 molecule Homo sapiens 0-3 26886923-0 2016 Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate. Sirolimus 130-139 CD4 molecule Homo sapiens 50-53 25682989-12 2015 CNI, as well as rapamycin and methylprednisolone, inhibited the in-vitro differentiation of Tfh from naive CD4(+) T cells. Sirolimus 16-25 CD4 molecule Homo sapiens 107-110 24683191-7 2014 DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +- 1.48%, rapamycin: 5.03 +- 0.66%; p < 0.001). Sirolimus 141-150 CD4 molecule Homo sapiens 44-47 24683191-10 2014 IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +- 0.66%, HC: 2.29 +- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +- 0.79%, rapamycin: 2.22 +- 0.60%; p < 0.001). Sirolimus 131-140 CD4 molecule Homo sapiens 34-37 23913957-7 2013 Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells. Sirolimus 0-9 CD4 molecule Homo sapiens 129-132 23968562-6 2013 Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+) forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+) CD38(+) lymphocyte activation gene (LAG)-3(+) Treg . Sirolimus 9-18 CD4 molecule Homo sapiens 86-89 24107844-6 2014 The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group. Sirolimus 134-143 CD4 molecule Homo sapiens 26-29 23968562-7 2013 In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+) FoxP3(+) regulatory T cell generation. Sirolimus 12-21 CD4 molecule Homo sapiens 159-162 23968562-7 2013 In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+) FoxP3(+) regulatory T cell generation. Sirolimus 12-21 CD4 molecule Homo sapiens 198-201 24123683-7 2013 However, the concurrent administration of rapamycin, with or without IL-2/anti-IL-2 Ab complexes, to the transplant recipients significantly improved Foxp3 stability in CD4 iTregs (and, to a lesser extent, CD8 iTregs), such that they remained detectable 12 wk after transfer. Sirolimus 42-51 CD4 molecule Homo sapiens 169-172 24123683-10 2013 These data demonstrate that CD4 iTregs can be produced rapidly in large, clinically relevant numbers and, when transferred in the presence of systemic rapamycin and IL-2, induce tolerance in transplant recipients. Sirolimus 151-160 CD4 molecule Homo sapiens 28-31 21565906-7 2011 RESULTS: We found that CD4(+)CCR6(+)CD161(+) T cells (i.e., precursor/committed Th17 cells) contaminate the T-regulatory cells cultured ex vivo in the absence of rapamycin. Sirolimus 162-171 CD4 molecule Homo sapiens 23-26 23165214-6 2013 The expression of HVEM on T cells and CD4+ T-cell subgroup decreased (p<0.05) while that on CD8+ T-cell subgroup remained roughly normal (p>0.05).The expression of HVEM on CD4+ Tregs increased significantly (p<0.05) in allo-renal recipients receiving Sirolimus regimen (p<0.05). Sirolimus 260-269 CD4 molecule Homo sapiens 178-181 23165214-7 2013 Though regulating the expression of HVEM/BTLA/CD160/LIGHT costimulatory system, Sirolimus-based regimen promotes inhibitory costimulatory signal in T cells and enhances the function of CD4+ Tregs in allo-renal recipients, which are in benefit of the control of transplant rejection as well as the induction and maintenance of transplant tolerance. Sirolimus 80-89 CD4 molecule Homo sapiens 185-188 23835553-3 2013 Using a co-culture system of human lipopolysaccharide (LPS)-matured moDCs and allogeneic naive CD4(+) T cells, we show that inhibition of mTOR by the immunosuppressive drug rapamycin reduced moDC maturation and promoted Th2 skewing. Sirolimus 173-182 CD4 molecule Homo sapiens 95-98 23426943-2 2013 To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4(+) Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy. Sirolimus 82-91 CD4 molecule Homo sapiens 108-111 22689677-8 2012 On days 30 and 90 post-transplant, sirolimus-treated patients had a significantly greater proportion of regulatory T cells among the CD4(+) cells in the peripheral blood, and isolated regulatory T cells were functional. Sirolimus 35-44 CD4 molecule Homo sapiens 133-136 22500984-8 2012 Interestingly, CD4(+) but not CD8(+) T lymphocytes were sensitive to T(reg) and rapamycin-induced apoptosis in vitro. Sirolimus 80-89 CD4 molecule Homo sapiens 15-18 22300641-3 2012 Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+) and CD8(+) T cells, as well as antigen-experienced CD28(+) CD95(+) memory and CD28(-) CD95(+) effector subpopulations. Sirolimus 18-27 CD4 molecule Homo sapiens 133-136 22366291-12 2012 A 2.5-fold expansion in CD4(+)CD25(+) lymphocytes occurred in recipients treated with fusion proteins and sirolimus that was not observed in the recipient treated with sirolimus alone. Sirolimus 106-115 CD4 molecule Homo sapiens 24-27 22366291-12 2012 A 2.5-fold expansion in CD4(+)CD25(+) lymphocytes occurred in recipients treated with fusion proteins and sirolimus that was not observed in the recipient treated with sirolimus alone. Sirolimus 168-177 CD4 molecule Homo sapiens 24-27 22366291-13 2012 CONCLUSIONS: Although IL-2/Fc, mIL-15/Fc, and sirolimus administered in this manner permitted modest prolongation of graft survival and expansion of CD4(+)CD25(+) T cells, tolerance was not achieved. Sirolimus 46-55 CD4 molecule Homo sapiens 149-152 21530600-0 2011 CD4(+)CD25(high)CD127(low) regulatory T cells in patients with stable angina and their dynamics after intracoronary sirolimus-eluting stent implantation. Sirolimus 116-125 CD4 molecule Homo sapiens 0-3 21538345-5 2011 Following activation, CXCR3-expressing CD4(+) Tregs were maintained in vitro in cell culture in the presence of the mammalian target of rapamycin (mTOR) inhibitor rapamycin, and we detected higher numbers of circulating CXCR3(+) FOXP3(+) T cells in adult and pediatric recipients of renal transplants who were treated with mTOR-inhibitor immunosuppressive therapy. Sirolimus 136-145 CD4 molecule Homo sapiens 39-42 21439133-1 2011 It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting. Sirolimus 26-35 CD4 molecule Homo sapiens 92-95 21094689-5 2011 The results showed that low-dose sirolimus selectively expanded Tregs, increased the expression of CD25(bright) and Foxp3 markers, and suppressed TCR- or allo-antigens induced CD4(+) T cell proliferation in vitro. Sirolimus 33-42 CD4 molecule Homo sapiens 176-179 21107839-3 2011 We were able to obtain more than 500-fold expansion of CD4(+)CD25(+) cells from CB CD4(+) cells using IL-15 and TGF-beta with rapamycin. Sirolimus 126-135 CD4 molecule Homo sapiens 55-58 21107839-3 2011 We were able to obtain more than 500-fold expansion of CD4(+)CD25(+) cells from CB CD4(+) cells using IL-15 and TGF-beta with rapamycin. Sirolimus 126-135 CD4 molecule Homo sapiens 83-86 21439133-1 2011 It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting. Sirolimus 26-35 CD4 molecule Homo sapiens 120-123 21439133-1 2011 It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting. Sirolimus 37-40 CD4 molecule Homo sapiens 92-95 21439133-1 2011 It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting. Sirolimus 37-40 CD4 molecule Homo sapiens 120-123 19903662-0 2010 Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Sirolimus 0-9 CD4 molecule Homo sapiens 85-88 20626386-3 2010 We found that donor BALB/c bone marrow-derived DCs (BMDCs) pharmacologically modified by the mTOR inhibitor rapamycin had significantly enhanced ability to induce CD4(+)CD25(+)Foxp3(+) iTregs of recipient origin (C57BL/6 (B6)) in vitro under Treg driving conditions compared to unmodified BMDCs. Sirolimus 108-117 CD4 molecule Homo sapiens 163-166 20406686-6 2010 Reconstitution of the CD4(+) T-lymphocyte subset was significantly lower with sirolimus versus cyclosporine over year 1, but CD8(+) reconstitution did not differ significantly between groups. Sirolimus 78-87 CD4 molecule Homo sapiens 22-25 20406686-7 2010 The proportion of naive CD4(+) T-lymphocytes showed an initial decrease with sirolimus versus cyclosporine. Sirolimus 77-86 CD4 molecule Homo sapiens 24-27 20406686-9 2010 Memory CD4(+) T-lymphocytes occurred more frequently in sirolimus- versus cyclosporine-treated patients during year 1. Sirolimus 56-65 CD4 molecule Homo sapiens 7-10 19903662-3 2010 The goal of this study was to compare the effects of cyclosporine A and rapamycin on the induction and suppressive functions of human CD4(+)CD25(+) Tregs in vitro. Sirolimus 72-81 CD4 molecule Homo sapiens 134-137 19903662-4 2010 METHODS: CD4(+)CD25(+) Tregs were induced in two-way mixed lymphocyte reaction (MLR) in the presence of rapamycin (Treg-Rapa) or cyclosporine A (Treg-CsA). Sirolimus 104-113 CD4 molecule Homo sapiens 9-12 19903662-8 2010 RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine. Sirolimus 23-32 CD4 molecule Homo sapiens 80-83 19715817-0 2009 Rapamycin--rather than FK506--might promote allograft tolerance induced by CD4+CD25+ regulatory T cells. Sirolimus 0-9 CD4 molecule Homo sapiens 75-78 20137731-7 2009 The percentage of CD4(+)Foxp3(+)Treg cells in total CD4(+) cells was significantly higher in rapamycin group and end-stage renal disease group than calcineurin inhibitors group (P < 0.01). Sirolimus 93-102 CD4 molecule Homo sapiens 18-21 20137731-7 2009 The percentage of CD4(+)Foxp3(+)Treg cells in total CD4(+) cells was significantly higher in rapamycin group and end-stage renal disease group than calcineurin inhibitors group (P < 0.01). Sirolimus 93-102 CD4 molecule Homo sapiens 52-55 18841360-0 2009 Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Sirolimus 53-62 CD4 molecule Homo sapiens 13-16 19453998-0 2009 Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Sirolimus 12-21 CD4 molecule Homo sapiens 44-47 18841360-5 2009 Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells. Sirolimus 53-62 CD4 molecule Homo sapiens 143-146 18841360-5 2009 Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells. Sirolimus 104-113 CD4 molecule Homo sapiens 143-146 18841360-6 2009 These results predict that Sirolimus or Sorafenib would reduce CD4(+)CD25(high) cells if administered prior to antigenic stimulation in an immunotherapy protocol. Sirolimus 27-36 CD4 molecule Homo sapiens 63-66 18841360-7 2009 However, administration of IL-2 protects CD4(+)CD25(high) T cells from cytotoxic effects of Sirolimus, a response that may be considered in design of therapeutic protocols. Sirolimus 92-101 CD4 molecule Homo sapiens 41-44 18559659-0 2008 Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Sirolimus 0-9 CD4 molecule Homo sapiens 64-67 18559659-2 2008 Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal for the induction and maintenance of peripheral tolerance. Sirolimus 0-9 CD4 molecule Homo sapiens 72-75 18559659-7 2008 However, nTregs isolated from type 1 diabetic patients under rapamycin treatment had an increased capability to suppress proliferation of CD4(+)CD25(-) effector T-cells compared with that before treatment. Sirolimus 61-70 CD4 molecule Homo sapiens 138-141 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Sirolimus 116-125 CD4 molecule Homo sapiens 155-158 18313267-6 2008 Addition of rapamycin to cultures containing IL-2 further increased the frequency and absolute number of functional CD4(+)CD25(+)FOXP3(+) Treg. Sirolimus 12-21 CD4 molecule Homo sapiens 116-119 18424697-1 2008 Addition of rapamycin to cultures of expanding natural CD4+CD25+Foxp3+ T regulatory cells (Tregs) helps maintain their suppressive activity, but the underlying mechanism is unclear. Sirolimus 12-21 CD4 molecule Homo sapiens 55-58 17996694-2 2007 Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells. Sirolimus 45-54 CD4 molecule Homo sapiens 20-23 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Sirolimus 116-125 CD4 molecule Homo sapiens 170-173 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Sirolimus 116-125 CD4 molecule Homo sapiens 170-173 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Sirolimus 127-136 CD4 molecule Homo sapiens 155-158 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Sirolimus 127-136 CD4 molecule Homo sapiens 170-173 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Sirolimus 127-136 CD4 molecule Homo sapiens 170-173 18021968-8 2007 The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients. Sirolimus 51-60 CD4 molecule Homo sapiens 18-21 18021968-8 2007 The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients. Sirolimus 62-71 CD4 molecule Homo sapiens 18-21 17287424-6 2007 CD4(+)CD25(high) cells that expressed FOXP3 underwent homeostatic peripheral expansion during immune reconstitution, more intense in patients who received sirolimus than in those who were given CsA. Sirolimus 155-164 CD4 molecule Homo sapiens 0-3 20477665-0 2007 The different effects of cyclosporin A and rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction. Sirolimus 43-52 CD4 molecule Homo sapiens 67-70 17182569-0 2007 Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. Sirolimus 97-106 CD4 molecule Homo sapiens 48-51 17453966-0 2007 Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Sirolimus 0-9 CD4 molecule Homo sapiens 23-26 17453966-10 2007 The addition of rapamycin inhibited expansion of non-regulatory T cells at doses > or =1 ng/mL while increasing suppressor activity and the percentage of CD4(+) CD25(+) CD27(+) Foxp3(+) cells. Sirolimus 16-25 CD4 molecule Homo sapiens 157-160 17182569-3 2007 Human purified CD4(+)CD25(high) T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4(+)CD25(low) or CD4(+)CD25(-) T cells did not. Sirolimus 146-155 CD4 molecule Homo sapiens 15-18 17182569-4 2007 The expanding pure populations of CD4(+)CD25(high) T cells were resistant to rapamycin-accelerated apoptosis. Sirolimus 77-86 CD4 molecule Homo sapiens 34-37 17182569-5 2007 In contrast, proliferation of CD4(+)CD25(-) T cells was blocked by rapamycin, which induced their apoptosis. Sirolimus 67-76 CD4 molecule Homo sapiens 30-33 17142730-6 2006 Interestingly, rapamycin promotes expansion of functional CD4+CD25+FOXP3+ Tregs also in type 1 diabetic patients, in whom a defect in freshly isolated CD4+CD25+ Tregs has been reported. Sirolimus 15-24 CD4 molecule Homo sapiens 58-61 17142730-6 2006 Interestingly, rapamycin promotes expansion of functional CD4+CD25+FOXP3+ Tregs also in type 1 diabetic patients, in whom a defect in freshly isolated CD4+CD25+ Tregs has been reported. Sirolimus 15-24 CD4 molecule Homo sapiens 151-154 17142730-0 2006 Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. Sirolimus 0-9 CD4 molecule Homo sapiens 43-46 17142730-7 2006 The capacity of rapamycin to allow growth of functional CD4+CD25+FOXP3+ Tregs, but also to deplete T effector cells, can be exploited for the design of novel and safe in vitro protocols for cellular immunotherapy in T cell-mediated diseases. Sirolimus 16-25 CD4 molecule Homo sapiens 56-59 16210336-7 2006 Accordingly, CD4+ CD25+ T(REG)s cultured in the presence of rapamycin displayed much stronger suppressive capacity than CD4+ CD25+ T(REG)s cultured in the presence of CsA. Sirolimus 60-69 CD4 molecule Homo sapiens 13-16 16778294-0 2006 Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Sirolimus 0-9 CD4 molecule Homo sapiens 63-66 16477233-9 2006 Next to lowering precursor frequencies, rapamycin also inhibited T cell expansion by inducing apoptosis in divided alloreactive CD4+ and CD8+ T cells. Sirolimus 40-49 CD4 molecule Homo sapiens 128-131 16210336-0 2006 Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Sirolimus 0-9 CD4 molecule Homo sapiens 89-92 16461044-5 2006 The percentages of CD8+ and CD4+ effector memory T cells, as defined by the CD3+CD45RO+CD27- phenotype, were significantly reduced in patients who received a sirolimus-eluting stent compared with the basal values. Sirolimus 158-167 CD4 molecule Homo sapiens 28-31 16210336-8 2006 In addition, CD4+ CD25+ T(REG) cells cultured in the presence of rapamycin, but not CsA, were able to suppress ongoing alloimmune responses. Sirolimus 65-74 CD4 molecule Homo sapiens 13-16 8286755-7 1994 In these studies, we showed that RAPA administration can inhibit MHC class I-restricted CD8+ or class II-restricted CD4+ T-cell-mediated graft rejection without compromising recipient survival. Sirolimus 33-37 CD4 molecule Homo sapiens 116-119 16237064-3 2005 Using anti-CD3 and anti-CD28 costimulation, CD4+ Th2 cell expansion was preserved partially in high-dose rapamycin (10 microM; Th2.rapa cells). Sirolimus 105-114 CD4 molecule Homo sapiens 44-47 15707399-4 2005 We studied the effects of the rapamycin derivative everolimus and the anti-CD25 monoclonal antibody basiliximab on the regulatory capacity of human CD4(+)CD25(+) cells in vitro. Sirolimus 30-39 CD4 molecule Homo sapiens 148-151 12176409-0 2002 Rapamycin blocks the generation of regulatory T cells facilitated by posttransplant infusion of donor T cells through increasing the apoptosis of thymic CD4(+)CD25(+) cells. Sirolimus 0-9 CD4 molecule Homo sapiens 153-156 35159680-10 2022 Repeated dosing of rapamycin PFC nanoparticles did not affect overall spleen T cell proliferation and responses to stimulation, although it significantly decreased the number of Foxp3+CD4+ T cells and NK1.1+ cells were observed. Sirolimus 19-28 CD4 molecule Homo sapiens 184-187 34949833-3 2022 Here, using a mouse model of acute infection with lymphocytic choriomeningitis virus (LCMV), we found that the serine/threonine kinase complex mammalian target of rapamycin complex 2 (mTORC2) is critical for the long-term persistence of virus-specific memory CD4+ T cells. Sirolimus 163-172 CD4 molecule Homo sapiens 259-262 35316218-0 2022 Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy. Sirolimus 0-9 CD4 molecule Homo sapiens 17-20 33329581-6 2020 In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet+Foxp3+(lo/hi) cells. Sirolimus 45-54 CD4 molecule Homo sapiens 10-13 31876121-3 2020 They demonstrated that CD4+ T cells isolated from Takayasu"s arteritis (TAK) are biased to differentiate into Th1 and Th17 cells because of mechanistic target of rapamycin complex 1 (mTORC1) hyperactivity. Sirolimus 162-171 CD4 molecule Homo sapiens 23-26 31624262-5 2019 Interestingly, numbers of IFN-gamma+ CD4+ T cells and serum IFN-gamma levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy. Sirolimus 108-117 CD4 molecule Homo sapiens 37-40 31191530-9 2019 Using cytomegalovirus (CMV) as model, our next-generation Rapamycin-treated (Rapa-)TCP showed consistently increased proportions of CD4+ T-cells as well as CD4+ and CD8+ central-memory T-cells (TCM). Sirolimus 58-67 CD4 molecule Homo sapiens 132-135 31191530-9 2019 Using cytomegalovirus (CMV) as model, our next-generation Rapamycin-treated (Rapa-)TCP showed consistently increased proportions of CD4+ T-cells as well as CD4+ and CD8+ central-memory T-cells (TCM). Sirolimus 58-67 CD4 molecule Homo sapiens 156-159 32535334-5 2020 These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro. Sirolimus 149-158 CD4 molecule Homo sapiens 6-9 32535334-5 2020 These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro. Sirolimus 149-158 CD4 molecule Homo sapiens 59-62 32381646-0 2020 Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice. Sirolimus 28-37 CD4 molecule Homo sapiens 61-64 32381646-9 2020 The combination of IL-2 and rapamycin has the potential to inhibit human islet-allograft rejection by expanding CD4+FOXP3+ Tregs in vivo and supressing effector cell function, and could be the basis of effective tolerance-based regimens. Sirolimus 28-37 CD4 molecule Homo sapiens 112-115 32488108-10 2020 The mTOR inhibitor rapamycin inhibited AP-induced DC-SIGN expression, CD4+ Th1/Th17 cell differentiation and the pro-inflammatory response via Myc. Sirolimus 19-28 CD4 molecule Homo sapiens 70-73 31074719-3 2020 The aim of the present study was to evaluate the effects of rapamycin, under the generic name sirolimus, on CD4+CD25+FoxP3+ Treg cells in rheumatoid arthritis (RA) patients with low disease activity or in DAS28 remission. Sirolimus 60-69 CD4 molecule Homo sapiens 108-111 31074719-3 2020 The aim of the present study was to evaluate the effects of rapamycin, under the generic name sirolimus, on CD4+CD25+FoxP3+ Treg cells in rheumatoid arthritis (RA) patients with low disease activity or in DAS28 remission. Sirolimus 94-103 CD4 molecule Homo sapiens 108-111